SABCS 2024: Palbociclib, Abemaciclib, and Ribociclib Can Be Considered Equivalent in the Treatment of HR-Positive/HER2-Negative Metastatic Breast Cancer

At SABCS 2024, two studies were presented, both analyzing the efficacy and safety of CDK4/6 inhibitor treatment with either palbociclib, abemaciclib, or ribociclib in patients with HR-positive/HER2-negative metastatic breast cancer. In this MEDtalk, Adam Brufsky, Hillman Cancer Center, University of Pittsburgh, Pennsylvania, USA, present the results of two large studies.